Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
A2,P3 would suffice Ndn71! There is/was the possibility that we get moved to Activ3/P3 to target hospitalised patients. In which case i'm sure we would all (doc included!) be happy for you to refer to it then as A3. In the meantime lets stick to the correct trial. p.s if you want to drop the capitals to save time on your phone i'm sure we can look past it! lol
No as Activ2 is for the home environment. Sprinter is hospitalised patients. If we gain p3 approval for both is is worth so much more. Yes at a later stage next year but a bump in the sp would be nice now and a further bump next year once we hopefully already have EUA for hospital patients.
Skippy the SP fell that day because we didn't meet our end point on the P2 home trial. Yes the board didn't help with their dour demeanour but essentially it was the news in the RNS that did it. Im execintg a much more polished Q&A with our news head of comms tomorrow. My guess is they have something significant to say.
upon (if) successful P3 hospital results this will be north of £10 before you can blink. Add in Activ2, Government pre-orders, EUA submission, licensing/partnerships, EMA shortlist etc etc and i'm expecting it be closer to £20. My timeframes have moved but my belief in the board and the product hasn't. Prediction, £10 by xmas, £20 by May 22. Followed by a potential take over end of 22 once they have cashed in on CV19.
Trek - circa £30m was set aside for manufacturing. Activ will be covered by the US. Expect the £30m stockpile will go towards supplying the NHS first. As we know no drug on shelf yet so they should still have the majority of that still in the bank.
Agree we may need more money to manufacture on a global scale and if that is the case any book build will need to be done after successful results. They can't ask for more money without showing their hand first. In which case the SP would be considerably higher and will only be seen a s appositive thing by the markets. There is also the consideration that any partnership or licence deal with 'big pharma' will sort any funding issues out. IMO i don't see it as we have other options. Unless of course we solely go it alone which I very much doubt will happen after numerous RM comments of partnering with pharma co's. I honestly believe behind the scenes they will have set up the whole plan and process to get the drug out to the road on successful results. Whether that be partnering or going straight to governments for preorders time will tell..
lots of PI's following the heard at the moment. Thought we may see another increase again today but seems most bought in on friday on the premise of a RNS this morning. Hopefully Polygon have hoovered up any weak sellers. It's time to sit on hands not play the RNS game.